InvenireX secures £2m in seed funding led by DSW Ventures to advance its disease detection platform.
The funding round was led by DSW Ventures with participation from XTX Ventures, Cambridge Technology Capital, angel investors, and Innovate UK.
Newcastle-based InvenireX has developed a DNA nanotechnology platform designed to detect early-stage disease markers. The technology utilises programmable structures and artificial intelligence to identify molecular targets with high sensitivity.
Newcastle biotech firm InvenireX has raised £2m in a seed funding round to push its DNA nanotechnology platform towards commercialisation. DSW Ventures led the investment, with backing from XTX Ventures, Cambridge Technology Capital, angel investors, and a grant from Innovate UK.
The company will direct the capital towards expanding its team and scaling pilot programmes as it seeks to bring its high-sensitivity disease detection system to market. The platform uses programmable DNA structures inside microfluidic chips to capture genetic markers, aiming to overcome limitations in standard testing methods like PCR.
From the founder
"Our machine could pick up cancer, HIV or sepsis earlier – any disease with a nucleic acid trace. We’re made of DNA – that’s the source code. If you can pick up traces of faults and errors in that code, you can detect problems across the board before symptoms appear. We’ve built the ultimate needle-in-a-haystack detector – a tool that we can put in the hands of scientists to enable the discoveries of tomorrow."
Dan Todd
CEO and founder at InvenireX
Use of funds
- 01Grow the team
- 02Fund the next phase of growth
